Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

Adults with obesity using a GLP-1 have a similar risk for obesity-related cancers as those who undergo bariatric surgery, ...

Unless you are from another planet, you’ve heard all about the new weight loss medications taking the world by storm. These ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...

While some Ozempic faces are appearing older with sunken cheeks, gaunt eyes and sagging neck skin — that doesn’t seem to be ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

Manhattan-based dentist Dr. Sandip Sachar and obesity medicine specialist Dr. Meghan Garcia-Webb discuss the prevalence of ...

Inadequate supply has created opportunities for bad actors seeking to profit from shortages, high costs and demand ...

HHS Secretary Robert F. Kennedy Jr. told Fox’s Sean Hannity recently that he believes the Trump has lost 30 pounds.

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.